A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

NCT02025192 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Positive Metastatic Breast Cancers

Interventions

DRUG: Tucatinib
DRUG: Capecitabine
DRUG: Trastuzumab

Sponsor

Seagen Inc.